Table 1.
Demographic and clinical sample characteristics
| Variables | Total cohort (n = 141) | APOE ɛ4 carriers (n = 47) | APOE ɛ4 non-carriers (n = 94) | |||
|---|---|---|---|---|---|---|
| Women (n = 74) | Men (n = 67) | Women (n = 24) | Men (n = 23) | Women (n = 50) | Men (n = 44) | |
| Aβ positive, n (%) | 28 (37.8) | 23 (34.3) | 14 (58.3) | 12 (52.2) | 14 (28) | 11 (25) |
| Education, years, mean (SD) | 16.3 (2.44) | 17.3 (2.47) | 16.5 (2.38) | 16.7 (2.85) | 16.1 (2.48) | 17.6 (2.21) |
| White, n (%) | 70 (94.6) | 63 (94) | 23 (95.8) | 22 (95.7) | 47 (94) | 41 (93.2) |
| African American or Black, n (%) | 3 (4.1) | 2 (3) | 1 (4.2) | 1 (4.3) | 2 (4) | 1 (2.3) |
| Asian, n (%) | 0 | 2 (3) | 0 | 0 | 0 | 2 (4.5) |
| More than one race, n (%) | 1 (1.4) | 0 | 0 | 0 | 1 (2) | 0 |
| FHS-CVD risk score, %, mean (SD) | 12.1 (5.76) | 26.7 (11.3) | 12.1 (5.89) | 29.6 (14.3) | 12.1 (5.76) | 25.1 (6.25) |
| Age, years, mean (SD) | 71.7 (6.08) | 72.6 (0.86) | 69.0 (6.04) | 73.4 (7.96) | 73.0 (5.7) | 72.1 (6.25) |
| Systolic blood pressure, mm Hg, mean (SD) | 134 (14.1) | 136 (14.8) | 136 (14.9) | 136 (13.9) | 134 (13.8) | 136 (15.4) |
| Total cholesterol, mg/dL, | 197 (38.6) | 181 (29.6) | 207 (38.6) | 181 (35.5) | 192 (38) | 182 (26.5) |
| mean (SD) | ||||||
| HDL cholesterol, mg/dL, | 64.6 (15.5) | 53.5 (11.0) | 67.1 (15.4) | 53.3 (12.0) | 63.4 (15.6) | 53.6 (10.6) |
| mean (SD) | ||||||
| Taking anti-hypertensive | 15 (20.3) | 11 (16.4) | 6 (25) | 7 (30.4) | 9 (18) | 4 (9.1) |
| medication, n (%) | ||||||
| Diabetic, n (%) | 6 (8.1) | 8 (11.9) | 2 (8.3) | 4 (17.4) | 4 (8) | 4 (9.1) |
| Smokers, n (%) | 1 (1.4) | 3 (4.5) | 0 | 1 (4.3) | 1 (2) | 2 (4.5) |
| Entorhinal cortex tau-PET SUVR, mean (SD) | 1.82 (0.398) | 1.65 (0.303) | 1.94 (0.492) | 1.77 (0.351) | 1.76 (0.334) | 1.58 (0.255) |
| Inferior temporal cortex tau-PET SUVR, mean (SD) | 1.73 (0.282) | 1.60 (0.172) | 1.8 (0.309) | 1.67 (0.212) | 1.70 (0.265) | 1.56 (0.134) |
| Meta-ROI temporal lobe tau-PET SUVR, mean (SD) | 1.62 (0.229) | 1.50 (0.150) | 1.68 (0.257) | 1.56 (0.185) | 1.59 (0.210) | 1.47 (0.119) |
| Time between FHS-CVD Assessment and tau-PET scan, years, mean (SD) | 4.77 (1.55) | 5.13 (1.55) | 4.79 (1.82) | 5.00 (1.21) | 4.76 (1.42) | 5.2 (1.71) |
Mean and SD are provided for continuous variables and n and % are provided for categorical variables. Aβ = amyloid-β; FHS-CVD = Framingham Heart Study cardiovascular disease; HDL = high density lipoprotein; SUVR = standardized uptake value ratio